Expertise in
12
conditions

Dr. Benjamin N. Voorhies

Oncology
Ihc Health Services Inc.
600 S Medical Center Dr, 
Saint George, UT 
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
Ihc Health Services Inc.
600 S Medical Center Dr, 
Saint George, UT 

Overview

Benjamin Voorhies is an Oncologist practicing medicine in Saint George, Utah.

Dr. Voorhies is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, Breast Cancer, Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 6 clinical trials. Dr. Voorhies is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in UT

Hospital Affiliations

Intermountain Health Garfield Memorial Hospital
Intermountain Health Cedar City Hospital
Intermountain Health Sevier Valley Hospital
Central Valley Medical Center - Cah
St. George Regional Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Ihc Health Services Inc.
600 S Medical Center Dr, Saint George, UT 84790

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2026
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab
A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: UV1, GM-CSF
Study Phase: Phase 1
Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)
Enrollment Status: Terminated
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

3 Total Publications

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2020
Similar Doctors
Expertise in
70
conditions
Expertise in
70
conditions
Referral may be required
Before you request

Revere Health

2019 E Riverside Dr Ste A200, 
Saint George, UT 
 (4.0 miles away)
801-433-2873
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Te is an Oncologist practicing medicine in Saint George, Utah. Dr. Te is highly rated in 70 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Angiosarcoma, Gastric Lymphoma, and Inflammatory Breast Cancer. Dr. Te is board certified in American Board Of Internal Medicine. Dr. Te is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Dixie Regional Medical Center Physicians

1380 E Medical Center Dr, 
Saint George, UT 
 (0.2 miles away)
435-251-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lincoln Nadauld is an Oncologist practicing medicine in Saint George, Utah. Dr. Nadauld is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pleuropulmonary Blastoma, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Bone Marrow Aspiration. Dr. Nadauld is board certified in American Board Of Internal Medicine. Dr. Nadauld is currently accepting new patients.

Expertise in
20
conditions
Dr. Terence D. Rhodes
Hematology | Oncology
Expertise in
20
conditions
Dr. Terence D. Rhodes
Hematology | Oncology
Referral may be required
Before you request

Intermountain Cancer Center - St George

600 South Medical Center Drive, Building 7, 
Saint George, UT 
 (4.0 miles away)
435-251-4900
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Terence Rhodes is the Senior Medical Director for Oncology for the Desert Region at Intermountain Health. With a robust background in medical oncology, Dr. Rhodes is dedicated to advancing quality patient care.Dr. Rhodes earned his MD and PhD from West Virginia University School of Medicine and the National Cancer Institute, where he specialized in Immunology, Microbiology, and Cell Biology. He completed his residency in Internal Medicine at WVU/Charleston Area Medical Center and his fellowship in Hematology/Oncology at Duke University Medical Center.His extensive training laid the foundation for his expertise in immuno-oncology and precision medicine. He has previously served as the Director of Immuno-Oncology and the Associate Director of Medical Oncology for Intermountain Health.Dr. Rhodes is passionate about scientific research and patient care, striving to make medicine better and deliver excellent care to as many people as possible. His vision includes advocating for providers and caregivers, ensuring clinical excellence, and fostering a culture of continuous learning and improvement. Dr. Rhodes is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Rhodes is board certified in American Board Of Internal Medicine. Dr. Rhodes is currently accepting new patients.

Frequently Asked Questions about Dr. Benjamin N. Voorhies

How do I make an appointment with Dr. Benjamin N. Voorhies?

You can book an appointment with Dr. Benjamin N. Voorhies by calling their office at 435-251-4900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Benjamin N. Voorhies a top-rated expert for Cholangiocarcinoma (Bile Duct Cancer)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Benjamin N. Voorhies is classified as an Distinguished expert for Cholangiocarcinoma (Bile Duct Cancer), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Benjamin N. Voorhies specialize in?

While Dr. Benjamin N. Voorhies is a Oncology, they have specific expertise in Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Benjamin N. Voorhies participate in research or clinical trials?

Yes. Dr. Benjamin N. Voorhies has published 3 articles and abstracts on conditions like Cholangiocarcinoma (Bile Duct Cancer). You can view a list of Dr. Benjamin N. Voorhies's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Benjamin N. Voorhies accept my insurance?

Dr. Benjamin N. Voorhies accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 435-251-4900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Voorhies's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile